Importantly, treatment with PYCR1-IN-1, a selective PYCR1 inhibitor, significantly suppressed EGFR- and TLR-induced tumor spheroid growth in multiple lung cancer cell lines, underscoring PYCR1’s potential as a therapeutic target. This evidence concerns the gene PYCR1 and neoplasm.